In Vitro Activity of Amphotericin B, Fluconazole and Voriconazole Against 162 Cryptococcus Neoformans Isolates From Africa and Cambodia

Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):506-8. doi: 10.1007/s10096-004-1136-2. Epub 2004 May 13.

Abstract

In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa ( n=52) and Cambodia ( n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.

Publication types

  • Comparative Study

MeSH terms

  • Africa / epidemiology
  • Amphotericin B / pharmacology*
  • Antifungal Agents / pharmacology
  • Cambodia / epidemiology
  • Cryptococcosis / diagnosis
  • Cryptococcosis / epidemiology
  • Cryptococcus neoformans / drug effects*
  • Cryptococcus neoformans / isolation & purification
  • Developing Countries
  • Drug Resistance, Fungal
  • Female
  • Fluconazole / pharmacology*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Pyrimidines / pharmacology*
  • Risk Assessment
  • Sampling Studies
  • Triazoles / pharmacology*
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Fluconazole
  • Voriconazole